公开(公告)号：US20240245677A1

公开(公告)日：2024-07-25

申请号：US18600097

申请日：2024-03-08

申请人： C4 THERAPEUTICS, INC.

发明人： Katrina L. Jackson ,  Christopher G. Nasveschuk ,  Rhamy Zeid ,  Ning Yin ,  Gesine Kerstin Veits ,  Moses Moustakim ,  Jeremy L. Yap ,  Minsheng He ,  Robert T. Yu ,  Matthew J. Schnaderbeck ,  Kathleen Neville ,  Siyi Jiang ,  Meiqi Li ,  Qianwei Liu ,  Manjie Zheng ,  Jia Li ,  Liwei Zhang

IPC分类号： A61K31/496 ,  A61P35/00

CPC分类号： A61K31/496 ,  A61P35/00

摘要： Selected BRD9 protein degradation compounds and morphic forms thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

公开(公告)号：US20230233692A1

公开(公告)日：2023-07-27

申请号：US18105735

申请日：2023-02-03

申请人： C4 Therapeutics, Inc.

发明人： James A. Henderson ,  Christopher G. Naveschuk ,  Kiel Lazarski ,  Victoria Garza ,  Moses Moustakim ,  Jae Young Ahn ,  Gesine Kerstin Veits ,  Morgan Welzel O'Shea ,  Ryan E. Michael ,  Jeremy L. Yap ,  Yanke Liang ,  Andrew Charles Good ,  Mark E. Fitzgerald ,  Robert T. Yu

IPC分类号： A61K47/55

CPC分类号： A61K47/55

摘要： Novel compounds which act as protein degradation inducing moieties for proto-oncogene tyrosine-protein kinase receptor (RET), which may be either wild type RET or a mutant form of RET.

公开(公告)号：US20240199581A1

公开(公告)日：2024-06-20

申请号：US18534395

申请日：2023-12-08

申请人： C4 Therapeutics, Inc.

发明人： Christopher G. Nasveshuk ,  Katrina L. Jackson ,  Yanke Liang ,  Robert T. Yu ,  Martin Duplessis ,  Mark E. Fitzgerald ,  Victoria Garza ,  Andrew Charles Good ,  Morgan Welzel O'Shea ,  Gesine Kerstin Veits ,  Cosimo Dolente ,  David Stephen Hewings ,  Daniel Hunziker ,  Daniela Krummenacher ,  Piergiorgio Franceso Tommaso Pettazzoni ,  Juergen Wichmann

IPC分类号： C07D401/14 ,  A61P35/00 ,  C07D405/14 ,  C07D471/10 ,  C07D491/107 ,  C07D495/10

CPC分类号： C07D401/14 ,  A61P35/00 ,  C07D405/14 ,  C07D471/10 ,  C07D491/107 ,  C07D495/10

摘要： The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer, mediated by mutant BRAF. The compounds efficiently degrade Class I, II and III mutant BRAF proteins.

公开(公告)号：US20230145336A1

公开(公告)日：2023-05-11

申请号：US18084380

申请日：2022-12-19

申请人： C4 Therapeutics, Inc.

发明人： Christopher G. Nasveschuk ,  Martin Duplessis ,  Mark E. Fitzgerald ,  Victoria Garza ,  Andrew Charles Good ,  Katrina L. Jackson ,  Yanke Liang ,  Moses Moustakim ,  Morgan Welzel O'Shea ,  Gesine Kerstin Veits ,  Jeremy L. Yap ,  Robert T. Yu ,  Cosimo Dolente ,  David Stephen Hewings ,  Daniel Hunziker ,  Bernd Kuhn ,  Piergiorgio Francesco Tommaso Pettazzoni ,  Fabienne Ricklin ,  Claus Riemer ,  Juergen Wichmann

IPC分类号： C07D471/04 ,  C07D519/00

CPC分类号： C07D471/04 ,  C07D519/00

摘要： Present invention provides compounds that cause specifically the degradation of BRAF. The present compounds are useful for the treatment of various cancers.